SARS-CoV-2 Virus 1x10^2 TCID50
Phase 1Biologic
SARS-CoV-2 Virus 1x10^2 TCID50 is one of 4 biologic programs targeting SARS-CoV-2 (COVID-19). It is currently in Phase 1.
2
Indications
2
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
3 competitors in SARS-Cov-2
#DrugCompanyPhaseTrials
1Veklury
GileadPreclinical
DPA-714-PET/MRI
UUniversity of Alabama at Birmingham
Phase 1
SARS-CoV-2 Virus 1x10^2 TCID50
IImperial College London
Phase 1
DPA-714 PET
UUniversity Hospital, Tours
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- IImperial College London